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Cognitive complaints after chemotherapy are common in breast cancer patients, but the neural bases 
for these complaints remain unclear. This pilot study explored resting‑state functional connectivity 
(FC) as a marker of subtle cognitive changes in breast cancer patients who experience cognitive 
complaints. Chemotherapy‑treated (n = 20, at least 6 months off therapy) and untreated (n = 17, 
disease‑control) female breast cancer patients with cognitive complaints and healthy controls (n = 20) 
were recruited. The FC of the right dorsolateral prefrontal cortex was calculated, and any correlations 
between this FC and neuropsychological assessments were determined. Chemotherapy‑treated 
patients with cognitive complaints displayed increased FC between the right dorsolateral prefrontal 
cortex and both the contralateral cerebellar lobule VII and the cerebellar vermis XI, compared to the 
disease‑control and healthy‑control groups, despite unimpaired neuropsychological performance. 
The increased FC was negatively correlated with executive function and attention in breast cancer 
survivors with cognitive complaints. Our pilot study findings provide evidence that cerebellar‑cortical 
FC changes may be a pathophysiological basis for chemotherapy‑related cognitive complaints. In 
addition, the FC changes have the potential to reflect minor or compensated cognitive function 
impairment in breast cancer patients.
Subjective cognitive complaints constitute one of the most common side effects of chemotherapy and also one of 
the most disturbing side effects in everyday  life1. Even when chemotherapy is not applied directly to the central 
nervous system (CNS), cognitive difficulties can be a side effect of systemic chemotherapy in non-CNS tumor 
 patients2. These cognitive effects of adjuvant systemic chemotherapy have been studied primarily in patients with 
breast  cancer3, which is the most frequently diagnosed cancer among women in developed  countries4. In light of 
the high percentage (17–75%) of breast cancer survivors who have reported cognitive  complaints5,6, understand-
ing and managing post-treatment cognitive changes in these patients are valid concerns.
Chemotherapy-treated breast cancer patients experience cognitive problems eight times more frequently than 
non-chemotherapy  patients7,8. Even though chemotherapy has been regarded as the source for post-treatment 
cognitive  complaints9, mild or undetected changes on neuropsychological assessment in post-chemotherapy 
 patients10 make it challenge to uncover declines in cognitive function. Inconclusive findings and associations 
between cognitive complaints and psychological symptoms, like depression and  anxiety11, also complicate the 
assessment of specific effects of chemotherapy on brain function.
Neuropsychological assessments alone have not been considered sensitive enough to determine minor 
cognitive  changes12,13, so neuroimaging techniques are being used to determine neural correlates of cognitive 
complaints in cancer survivors. In particular, resting-state functional magnetic resonance imaging (rs-fMRI) 
is an objective method to examine brain network changes in breast cancer survivors who have undergone 
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 chemotherapy14. Prior studies comparing chemotherapy treated breast cancer patients with healthy controls 
have shown alterations in the executive  network15; disrupted regional networks in the frontal, temporal, and 
striatal  areas16; changes in the functional connectivity (FC) of the anterior cingulate  cortex17 or the anterior 
 hippocampus18; and alterations in amplitude of low-frequency  fluctuation14. Kesler et al.19 demonstrated that 
damage to the default-mode network could discriminate chemotherapy treated patients from non-chemotherapy 
treated patients and healthy controls. Although the vast majority of studies focused on cognitive impairment 
instead of cognitive complaints when recruiting chemotherapy-treated patients, Piccirillo et al.20 compared 
chemotherapy treated breast cancer patients who self-report cognitive impairment to patients who did not 
self-report cognitive impairment. Disrupted frontoparietal FC was found in subjects who suffer from cogni-
tive  complaints20, and this finding suggested there may be alterations in FC in patients who have cognitive 
complaints compared to patients without cognitive complaints. To further our understanding of the effects of 
chemotherapy on cognitive complaints, patients who self-report cognitive complaints should be recruited, and 
within this group, patients who were treated with chemotherapy should be compared to patients who were not 
treated with chemotherapy. The targeted investigation of patients with cognitive complaints in their daily lives 
may not only increase the understanding of compromised cognitive function but also provide insight into the 
cognitive complaints themselves.
In prior FC studies investigating cognitive functions in breast cancer patients after chemotherapy, the dor-
solateral prefrontal cortex (DLPFC) was investigated because of its well-known role in mediating a variety of 
cognitive  processes21. During executive function tasks, reduced DLPFC activation was found in the chemotherapy 
treated patients compared to a non-chemotherapy treated  patients22. Based on rs-fMRI results comparing breast 
cancer patients treated with chemotherapy to healthy controls, increased FC from the right DLPFC to the right 
middle temporal gyrus and the precuneus, as well as decreased FC of the right DLPFC with right inferior frontal 
gyrus, was  demonstrated15. In a previous study which showed a separation of the DLPFC seed  voxels23, the right 
posterior-dorsal subregion was strongly associated with working memory and cognitive action control. Therefore, 
by choosing the right posterior DLPFC (MNI  coordinates23: x = 37, y = 33, z = 32, and radius = 10 mm) as the seed 
region to calculate its FC with the whole brain, the present pilot study explored using resting-state FC from the 
DLPFC as a marker of subtle or compensated cognitive changes in breast cancer patients who experience cogni-
tive complaints. We hypothesized that cognitive complaints in chemotherapy-treated patients, which could not be 
detected using neuropsychological performance assessments, could be uncovered by assessing FC with rs-fMRI. 
We also expected that psychological factors, such as depression and anxiety, may partially account for cogni-
tive difficulties, but that FC related to cognitive complaints would not be attributable to psychological factors.
Materials and methods
Participants. Breast cancer patients with cognitive complaints from the Severance Hospital of the Yonsei 
University Health System in Seoul, where they were treated with a standard-dose chemotherapy regimen (doc-
etaxel/adriamycin/cyclophosphamide), were recruited by posting advertisements that we were seeking “female 
breast cancer patients (30–85  years old) who feel a decline in their cognitive functions” for a clinical study. 
Recruitment was also done via a website posting in an online community of breast cancer patients. There was 
restricted access to complete medical records, including detailed chemotherapy regimens, for the seven patients 
who were recruited through this online community. All breast cancer patients had completed chemotherapy 
at least 6 months prior to enrollment in the study, excluding continued hormonal therapy. Participants were 
excluded if they had (a) uncontrolled comorbid medical conditions; (b) history of psychiatric illness; (c) evi-
dence of other types of cancer or recurrence of breast cancer; or (d) history of brain metastasis, brain injury, or 
any other neurological illness. Healthy controls who did not have cognitive complaints were recruited via adver-
tisements on local websites. All participants were assessed using the Structured Clinical Interview for Diagnos-
tic and Statistical Manual of Mental Disorders, 4th edition (SCID-I), the Hamilton rating scale for depression 
(HRSD)24, and the Hamilton anxiety scale (HAS)25. The participants included 20 patients with breast cancer 
who were treated with chemotherapy (group C+), 17 age-matched patients with breast cancer who were not 
treated with chemotherapy (group C−), and 20 healthy controls (group HC). Of the 57 participants, one non-
chemotherapy patient and one healthy control were not included in the fMRI analyses because of data loss due 
to an MRI scanner error. One healthy control was excluded due to excessive motion artifacts (> 2 mm translation 
or > 2° rotation on a frame-to-frame basis). Thus, 54 participants were included in the final study analyses. A 
detailed flow diagram for the study is shown in Supplementary Fig. S1.
This study was carried out in accordance with the Declaration of Helsinki and was approved by the institu-
tional review board at Severance hospital, Seoul, Korea (4-2014-0235). All subjects provided written informed 
consent to participate in the study.
Neuropsychological assessment. The most frequent cognitive problems reported by breast cancer sur-
vivors include changes in attention, processing speed, executive function, and  memory9. Therefore, we evaluated 
neurocognitive function in all participants using a battery of neuropsychological tests that covered the afore-
mentioned domains: (1) attention and concentration (WAIS Digit  span26); (2) processing speed (WAIS Digit 
 symbol26); (3) executive function [Raven’s standard progressive matrices (SPM)27]; and (4) memory [Rey-Kim 
auditory verbal learning test (RAVLT)28].
Image acquisition. The rs-fMRI data were acquired using a 3.0 T MRI scanner (Ingenia CX; Philips, Erlan-
gen) equipped with a 32-channel head coil. Data were obtained while participants rested in the scanner with 
their eyes open and fixated on a white cross at the center of a screen. A T2*-weighted gradient echo planar imag-
ing (EPI) sequence was used: repetition time (TR) = 2000 ms, echo time (TE) = 30 ms, flip angle = 90°, 31 inter-
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leaved slices, slice thickness = 4 mm, matrix size = 80 × 80, field of view (FOV) = 220 × 220 mm. All participants 
were recorded for 5.5 min (165 volumes), and two initial dummy volumes were obtained to ensure magnetiza-
tion stability. High-resolution structural T1-weighted images using a turbo field echo sequence were acquired 
using the following parameter settings: spin-echo, TR = 9.9 ms, TE = 4.6 ms, flip angle = 8°, 220 coronal slices, 
slice thickness = 1 mm, matrix size = 224 × 224, FOV = 224 × 224 mm.
Image preprocessing. The rs-fMRI data were analyzed using AFNI software (version 20.1.0229). The first 
three volumes of the functional dataset were discarded for signal stabilization. To suppress local spikes in the 
EPI signals, we performed de-spiking for each voxel time-series. Rigid-body registration of EPI volume to a base 
EPI volume was conducted for head motion correction. Physiological noise (i.e., respiratory and cardiac arti-
facts) were corrected using Physiological Estimation by Temporal Independent Component Analysis (PESTICA, 
https:// www. nitrc. org/ proje cts/ pesti ca/), which is a tool to distinguish physiological signals from rs-fMRI data 
and then remove the physiological  noise30. Slice-timing correction was performed for all slices within a volume. 
Co-registration to the high-resolution structural T1 images was performed, and then spatial normalization was 
carried out by affine transformations. The affine transformation parameters were obtained from normaliza-
tion of the T1 images into Montreal Neurological Institute (MNI) space using the MNI avg152T1 template. T1 
images were corrected for nonuniformity and striped skull before normalization into MNI space. The normal-
ized T1 images were segmented into grey matter (GM), white matter (WM), and cerebrospinal fluid (CSF) by 
segmentation tool of FSL software (http:// fsl. fmrib. ox. ac. uk/)31,32, and then the segmented images were binarized 
to create binary masks. Large ventricle (LV) masks were manually selected from the CSF mask. Voxels of EPI 
volume were resampled with 2 × 2 × 2  mm3 isotropic voxels, using nearest-neighbor interpolation. A temporal 
bandpass filtering was applied at 0.009 < f < 0.08 Hz. Nuisance signals, which included six head motion correc-
tion parameters and non-neural sources of variance from the eroded WM and LV masks, were regressed out. 
Framewise displacement (FD) was calculated based on the sum of the absolute value of the derivative of the six 
motion  parameters33 and outlier volumes at time-points with an FD > 0.3 mm. In addition, the one preceding 
and the one following the time-point were excluded. Spatial smoothing was performed using an isotropic Gauss-
ian kernel of full width at half-maximum of 6 mm.
Functional connectivity analysis. The FCs between the averaged blood-oxygen-level-dependent time 
course from the right posterior DLPFC (MNI  coordinates23: x = 37, y = 33, z = 32, and radius = 10 mm) and the 
time courses from the whole brain were computed. The right posterior DLFPC, which was masked with the GM 
mask, was used as a seed for regions of interest (ROIs). The correlation coefficients were converted into z-values 
using Fisher’s r-to-z transformation to obtain the FC strengths.
Analysis of variance (ANOVA) and analysis of covariance (ANCOVA) using age, years of education, depres-
sion scores, and anxiety scores as covariates were performed to compare FC strengths among the C+, C−, and 
HC groups. Statistical significance was set to a voxel-wise threshold of P < 0.001 within a cluster extent threshold 
of 65 voxels, which corresponds to a corrected family-wise error of P < 0.05. Significance thresholding for group 
analyses was conducted using 3dClustSim, which was available in the AFNI software suite. The mean values of 
FC strength were extracted in regions showing significant differences in FC.
Group and correlative analyses. A one-way ANOVA, with group-type as a fixed factor, was used to 
assess differences among groups for normally distributed continuous variables. Kruskal–Wallis tests were per-
formed for nonparametric variables. To assess group performance differences for the neuropsychological tests, 
‘years of education’ was included as a covariate. We applied square transformation to Raven’s SPM and RAVLT-
recall, cube transformation to RAVLT-recognition, square root transformation to HRSD, and fourth root trans-
formation to HAS with a normal distribution. All variables had skewness levels that were acceptable for statisti-
cal analysis (< 1.0) after transformation. Pearson’s partial correlations, with an adjustment for years of education, 
were used to analyze correlations between the following parameters: neurocognitive domains and depression 
and anxiety in breast cancer patients and neurocognitive functions and FC. Correlations between neurocogni-
tive functions and FC were then further explored with an adjustment for years of education and scores of depres-
sion and anxiety.
Results
Demographic and clinical characteristics. Demographic and clinical characteristics of breast cancer 
patients and healthy controls are summarized in Table 1. Age and years of education were not significantly differ-
ent among the C+, C−, and HC groups; however, compared to the HC group, the breast cancer groups (C+ and 
C−) had significantly higher depression and anxiety scores, despite the exclusion of major psychiatric illnesses, 
as determined by SCID-I assessment. The C+ group did not differ from the C− group with regard to depression 
and anxiety scores.
Neuropsychological assessments. There were no significant group differences using the neuropsycho-
logical tests (Table 2). In the 36 breast cancer patients with cognitive complaints, lower attention/concentration 
values were correlated with depression (r =  − 0.37, P = 0.030) and anxiety symptoms (r =  − 0.41, P = 0.013), and 
lower executive function values were also correlated with higher scores for anxiety (r =  − 0.37, P = 0.031).
Functional connectivity analyses. FC analyses using age, years of education, depression scores, and 
anxiety scores as covariates among the C+, C−, and HC groups demonstrated increased FCs between the right 
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DLPFC seed region and the left cerebellar lobule VII (DLPFC-lobule VII) and between the DLPFC and the 
cerebellar vermis XI (DLPFC-vermis XI) in the C+ group compared to those in the control groups (C− and HC) 
(Fig. 1, Table 3). FC analyses without covariates were performed because the analyses with covariates had low 
statistical power due to small sample sizes. Both methods yielded similar results (Supplementary Table S1).
Correlation analysis between neurocognitive performance and FC in breast cancer 
patients. In breast cancer patients with cognitive complaints (n = 36), the FC of the DLPFC-lobule VII was 
negatively correlated with executive function (r =  − 0.38, P = 0.026) (Fig. 2A). For FC of the DLPFC-vermis XI, 
attention/concentration was inversely correlated (r =  − 0.34, P = 0.044) (Fig. 2B). When the correlation analysis 
was adjusted for the scores of depression and anxiety, the correlation between FC of the DLPFC-lobule VII and 
executive function (r =  − 0.36, P = 0.039) remained.
Discussion
This pilot study investigated resting-state FCs in the brains of breast cancer patients with cognitive complaints 
after chemotherapy compared to FCs in the brains of patients not treated with chemotherapy to reveal the effect 
of chemotherapy on cognitive complaints. The neurocognitive performance of breast cancer patients treated 
with chemotherapy was not significantly different from that of the disease-control and healthy control groups. 
However, a greater activation of the brain functional network area was shown in breast cancer survivors treated 
with chemotherapy. The FC analyses in our study used the scores of depression and anxiety as covariates, so the 
functional network changes could be considered unrelated to these psychological factors. We demonstrated an 
increased FC between the DLPFC and both the contralateral cerebellar lobule VII and the cerebellar vermis IX 
in the C+ group compared to both control groups. In addition, the FC strengths were correlated with attention 
and executive function. These results suggest that cerebellar-cortical FC changes in patients exposed to chemo-
therapy may be associated with their cognitive complaints.
Table 1.  Demographic and clinical characteristics of patients and controls. † Corrected P-values are derived 
from post-hoc comparisons with Bonferroni correction. C+ patients treated with chemotherapy, C−, patients 
not treated with chemotherapy, HC healthy controls, HAS Hamilton anxiety scale, HRSD Hamilton rating scale 
for depression.
C+ (n = 20) C− (n = 16) HC (n = 18)
Statistical analysis
Value P-value Post-hoc P-value†
Age, mean (SD), years 52.0 (5.9) 50.8 (10.7) 52.8 (7.7) F = 0.28 0.758
Education, mean (SD), years 13.9 (3.4) 15.5 (3.5) 13.6 (2.7) F = 1.76 0.182
Breast cancer stage




Hormonal therapy, no. (%) 13 (65.0) 14 (87.5)
Radiotherapy, no. (%) 14 (70.0) 11 (68.8)
Depression HRSD, mean (SD) 5.2 (4.9) 3.6 (2.2) 1.9 (2.1) F = 4.37 0.006
C+ vs. C− 1.000
C+ vs. HC 0.006
C− vs. HC 0.061
Anxiety HAS, mean (SD) 4.5 (3.5) 2.6 (1.3) 1.5 (1.8) F = 7.22  < 0.001
C+ vs. C− 0.269
C+ vs. HC  < 0.001
C− vs. HC 0.053
Table 2.  Summary of neuropsychological assessments. Values are means (SD). Higher scores on WAIS 
Digit span, WAIS Digit symbol, SPM, and RAVLT indicate better performance. C+ patients treated with 
chemotherapy, C− patients not treated with chemotherapy, HC healthy controls, RAVLT Rey-Kim auditory 
verbal learning test, SPM Raven’s standard progressive matrices, WAIS Wechsler adult intelligence scale.
Domain Test C+ (n = 20) C− (n = 16) HC (n = 18) P-value
Attention/concentration WAIS digit span 11.4 (2.3) 12.4 (2.0) 10.9 (2.6) 0.440
Processing speed WAIS digit symbol 11.4 (3.9) 12.5 (2.9) 12.5 (2.7) 0.404
Executive function SPM 38.4 (9.7) 44.6 (9.3) 39.2 (10.0) 0.517
Memory
RAVLT-recall 13.5 (3.3) 12.8 (2.9) 13.8 (1.9) 0.341
RAVLT-recognition 13.7 (2.8) 13.3 (2.2) 14.7 (1.0) 0.158
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Figure 1.  Group analysis results for FC of the right DLPFC. (A) The seed ROI in the right DLPFC (A-1) 
and its example on T1-weighted MRI of individual subject (A-2). The breast cancer patients treated with 
chemotherapy showed increased FC compared to control groups between the seed region of the right DLPFC 
and the left cerebellar lobule VII (B) and the cerebellar vermis XI (C). Brain maps of results of ANCOVA were 
superimposed on the MNI152 T1 template. The bar graph shows the average FC strength with the right DLPFC 
in the regions showing significant differences among groups. FC functional connectivity, DLPFC dorsolateral 
prefrontal cortex.
Table 3.  Group analysis results for functional connectivity of the right DLPFC. x, y, and z refer to left–right, 
anterior–posterior, and inferior-superior dimensions, respectively; F refers to the score at those coordinates. 
DLPFC dorsolateral prefrontal cortex.
Brain area Voxels F x y z
Cerebellar lobule VII, left 77 9.56  − 14  − 76  − 52
Cerebellar vermis XI 68 15.26 2  − 48  − 34
6
Vol:.(1234567890)
Scientific Reports |        (2021) 11:12105  | https://doi.org/10.1038/s41598-021-91447-1
www.nature.com/scientificreports/
Self-reported cognitive complaints are often overlooked or dismissed in clinical settings when they supported 
by objective testing results, as in our observation of non-significant differences in neuropsychological perfor-
mance for breast cancer patients with cognitive complaints. By recruiting patients who self-report cognitive com-
plaints and then comparing patients treated with chemotherapy to patients not treated with chemotherapy, the 
brain-network alterations seen in the chemotherapy-treated patients may suggest a potential biomarker for these 
complaints, which are related to the effects of chemotherapy, not to breast cancer or other cancer-treatments. 
Several candidate mechanisms have been proposed to explain such chemotherapy-associated brain changes. 
Increases in oxidative DNA damage, chemotherapy-induced hormonal changes, and the neurotoxic effects of 
inflammatory cytokines could all possibly increase the vulnerability of the brain to network changes associated 
with  chemotherapy34,35. Consistent with recent studies showing widespread alterations in brain networks, rather 
than regionally specific effects of  chemotherapy16,36–38, our FC-change findings offer additional convergent data 
supporting brain-network abnormalities as a mechanism for explaining cognitive complaints after chemotherapy.
Our findings showing an increased FC between the DLPFC and cerebellar regions in breast cancer survivors 
treated with chemotherapy may indicate alterations in cerebrocerebellar interconnections. Extensive cerebellar 
involvement in cognitive functions is well  known39,40. Moreover, multiple cerebrocerebellar couplings have been 
observed involving the brain resting-state41. The cerebellar contributions to each cerebral network are distinct and 
 selective41; for example, the neocerebellum is related to the executive control network (ECN), especially crus I and 
II with extensions into lobules VI–VII, and constitutes a crucial node for executive  function42. Thus, the increased 
FC between DLPFC and lobule VII in our study may reflect a hyperactivation of the ECN due to compensatory 
mental efforts in chemotherapy-treated patients with cognitive complaints. The correlation between the FC of the 
DLPFC-lobule VII and executive function scores also suggests the possibility of compensatory neuroplasticity 
maintaining cognitive performance in chemotherapy-treated survivors. The involvement of the neocerebellum 
in emotion has also been  documented42, however, controlling for depression and anxiety as covariates in our 
FC analysis suggested that these FC changes were unlikely to be due to any differences in psychological factors 
among groups. The correlation between FC of the DLPFC-lobule VII and executive function scores even after 
controlling for depression and anxiety suggests a cognitive role of FC, regardless of psychological factors.
Although a role for the vermal IX area has yet to be resolved, a stronger FC with the default-mode net-
work (DMN) compared to the prefrontal cortices was demonstrated in a previous rs-fMRI study of healthy 
 participants43. Therefore, increased FC of the DLPFC-vermis IX area in our patients could suggest a disruption 
of distinct cerebellar contributions to the intrinsic cerebral network. The aberrant coupling of cerebrocerebel-
lar networks may interrupt subtle cognitive processes, resulting in cognitive complaints of the patients with 
chemotherapy. The correlation between the FC of the DLPFC-vermis IX area and attention scores in our patient 
group increases the likelihood of aberrant FC involvement in cognitive disturbances. Because the exploratory 
correlation analysis adjusted for depression and anxiety found a non-significant correlation between FC of the 
DLPFC-vermis IX and attention scores, these psychological factors may play a role in the relationship between 
FC and cognitive function, which could be revealed by future studies including mediation analyses and larger 
sample sizes. A troublesome confounder has been that psychological distress can undermine cognitive function in 
Figure 2.  Correlation between neurocognitive performance and FC in breast cancer patients. (A) The 
significant partial correlation between the FC of the DLPFC-lobule VII and square-transformed scores of the 
Raven’s SPM, with an adjustment for years of education. (B) The significant partial correlation between the 
FC of the DLPFC-vermis XI and scores of the WAIS Digit span, with an adjustment for years of education. To 
visualize these partial correlations, variables were regressed onto years of education using a linear regression. 
Values reported in the scatterplot are non-standardized residuals. FC functional connectivity, DLPFC 
dorsolateral prefrontal cortex, r partial correlation coefficient, SPM standard progressive matrices, WAIS 
Wechsler adult intelligence scale.
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cancer patients who have an elevated risk for depression and  anxiety12, and a relationship between the perception 
of cognitive complaints and psychological factors has also been  documented11,12. In our study, high scores for 
depression and anxiety were correlated with both attention and executive functions in the breast cancer groups 
(C+ and C−) compared to the HC group. Those correlations suggest that psychological factors that underlie 
cognitive complaints should be addressed in survivors who report cognitive problems in their daily lives. Moreo-
ver, researchers should be aware of the confounding effects of psychological symptoms on studies of cognitive 
complaints, which was the reason we used depression and anxiety as covariates when performing FC analyses.
The present pilot study has several limitations. One is the limited heterogenous sample in terms of chemo-
therapy regimens and disease stages. For example, we were unable to evaluate whether any functional network 
alterations were related to individual chemotherapy regimens. Additionally, although a previous  study44 showed 
non-significant effects of hormonal changes on cognitive function in breast cancer patients, we did not control 
for menopausal status, the effects of  estrogen45, or hormone-replacement  therapy46,47 on cognitive decline. The 
cross-sectional design of the present study also limited our understanding of any causal relationships between 
brain functional network changes and subjective cognitive problems. Therefore, prospective studies with large 
and homogeneous populations are needed to yield a definite conclusion. Lastly, our FC analysis included the 
comparison between C+ and C−, which was necessary to elucidate the effect of chemotherapy in patients with 
cognitive complaints; however, the effects of breast cancer or cognitive complaints themselves could not be 
determined. An elaborate 2 × 2 × 2 design (‘breast cancer patients vs. healthy individuals’ × ‘with vs. without 
cognitive complaint’ × ‘C+ vs. C−’) could provide a more thorough understanding by extensively controlling 
potential confounding effects.
In conclusion, we have demonstrated an increased resting-state FC between the DLPFC and cerebellar regions 
in breast cancer survivors who experienced cognitive complaints after chemotherapy treatment. Although many 
of these survivors still scored in the normal range on neuropsychological tests, the correlation between altered 
FC and cognitive performance suggests that cognitive complaints may be the result of compensatory processes 
of brain networks.
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